Introduction {#sec1-1}
============

Radiation plays an important role in the management of breast cancer. Postmastectomy radiotherapy (RT) is highly effective in preventing chest wall recurrences.\[[@ref1]\] Postoperative RT to chest wall after mastectomy is usually given in 25 fractions of 2 Gy fraction size in 5 weeks followed by a boost if needed. Hypofractionated RT, whereby a fraction size of \>2 Gy is utilized, has gained significant popularity as adjuvant treatment postbreast conserving surgery, based on the results of various randomized trials.\[[@ref2][@ref3][@ref4][@ref5]\] However, the data on the use of postmastectomy hypofractionated RT and its effects on normal tissues are still limited.

Based on the radiobiological predictions, it is clear that the use of \>2 Gy produces unfavorable long-term sequelae. Adhering to the radiobiological principles, it has been quantified that the healthy tissues of breast and underlying structures are sensitive to fraction size, volume irradiated, and total dose delivered. Using linear quadratic model, α/β values for late reacting tissues are found to be 5 Gy or less.\[[@ref6]\] α/β ratio is the dose D at which the components of cell killing that are proportional to dose, i.e., αD equal those that are proportional to the square of dose, i.e., βD2. Therefore, even small changes in fraction sizes can produce relatively large changes in effects of RT on the late-reacting tissues. Postmastectomy, chest wall irradiation exposes organs such as lungs and heart to a significant amount of radiation which increases the normal tissue complications. These complications are inevitable, and given the long-term survival of breast cancer patients, these long-term adverse effects should be quantified. Moreover, although new modalities such as intensity-modulated RT and three-dimensional RT have come a long way in sparing normal tissues, use of two-dimensional treatment with cobalt 60 is still prevalent in developing countries like ours.

Using postmastectomy hypofractionated RT in conjunction with conventional planning can impair normal tissue function in the long run. To quantify the late effects of hypofractionated RT on pulmonary, cardiac, brachial plexus, and lymphedema sequelae is the main objective of this study, and to find out the correlation of patient, tumor, and treatment characteristics with these late effects is the secondary objective to carry out this study.

Materials and Methods {#sec1-2}
=====================

Patients {#sec2-1}
--------

A total of 216 female patients with breast cancer following mastectomy were followed from January 2011 to January 2016. Study was approved by the Local Ethics Committee. Eligibility criteria include female patients, postmastectomy, with histologically proven disease, \>20 years age group with either stage 1--3. All patients with breast-conserving surgery, positive margins, chest malformations, chronic cardiac or pulmonary disease, pregnant or lactating were excluded from evaluation.

Radiotherapy {#sec2-2}
------------

Hypofractionated schedules used were either 42.5 Gy in 16 fractions with 2.65 Gy fraction in 22 days or 40 Gy in 15 fractions with 2.66 Gy fraction in 19 days depending on physician\'s preference. RT was delivered by Theratron 780 teletherapy cobalt 60 machine, with the intention to treat chest wall along with regional lymphatics depending on the histopathology report. Tangential RT portals were utilized for chest wall RT and direct portal for supraclavicular/axillary fields. Bolus was used on alternate days. Two-dimensional planning was done.

Patient assessment {#sec2-3}
------------------

Echocardiography and pulmonary function tests (PFTs) were done for all patients before the start of RT and then after 3 monthly intervals till 1 year, followed by 6 monthly assessments till last follow-up. Percentage decline in ejection fraction was used to evaluate cardiac reactions, while for pulmonary function, measurements were recorded as percentages of predicted values. For lymphedema, grading percentage change in inter-limb discrepancy in volume or circumference at point of greatest visible difference in conjunction with other points such as obscuration of anatomic architecture, pitting edema, and interference with daily life was taken into account. And finally, for brachial plexopathy, grading patient\'s symptomatology along with active daily life score was used. This grading is in accordance with the Common Terminology Criteria for Adverse Events version 3.0.

Statistical analysis {#sec2-4}
--------------------

Descriptive statistics were used to present the data. For repeated measurements, analysis of variance was utilized to assess the difference in function values at different times and to correlate the respective function values at different times with multiple demographic variables. Pearson Chi-square test was used to assess correlation of numerical variables.

Results {#sec1-3}
=======

Patient characteristics {#sec2-5}
-----------------------

A total of 216 patients were followed from January 2011 to January 2016 for the effects of hypofractionated RT on normal tissue toxicity especially pertaining to cardiac, pulmonary, brachial plexus, and lymphedema sequelae in postmastectomy breast cancer patients. Median follow-up was 42 months. The majority of the patients were in 40--60 years age group, with median age of 49 years \[[Table 1](#T1){ref-type="table"}\]. Sixteen percent of the females were either active or ex-smokers. Twenty-two percent had diabetes, and 24.5% were known hypertensive. The majority had stage two or three disease with ductal histology being more common. Axillary dissection was done in 175 patients with adequate dissection meaning more than equal to ten nodes dissected was performed in 117 patients. All patients were given full course of chemotherapy before the start of RT. Tamoxifen was prescribed as hormonal therapy to 103 patients, while 39 were given aromatase inhibitor (either anastrozole or letrozole). The supraclavicular field was prescribed to 131 patients based on their histopathological features.

###### 

Patient, tumor, and treatment characteristics
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Toxicity analysis {#sec2-6}
-----------------

We mainly restricted our analysis to late adverse events which are described as those occurring \>6 months after the completion of RT \[[Table 2](#T2){ref-type="table"}\]. Our main organs of interest were heart, lungs, brachial plexus, and lymphedema, because these are the main organs at risk during chest wall irradiation, and their long-term toxicity adversely affects the quality of life of an individual.

###### 

Toxicity analysis (*n*=216)
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Cardiac {#sec2-7}
-------

Thirty-two out of 216 patients developed ≥ Grade (Gr) 2 late cardiac toxicity, and out of which, one patient had congestive cardiac failure which was poorly controlled by medication.

Pulmonary {#sec2-8}
---------

About 10.2% of patients had ≥Gr2 late pulmonary toxicity. Although symptomatic pneumonitis was rare in our study, 5 patients had clinically significant percentage decline in PFTs over their predicted values.

Lymphedema {#sec2-9}
----------

Arm circumference was taken 5 cm above and below the olecranon and at wrist level and was compared with the opposite arm. Sixty-two patients developed \>10% inter-limb discrepancy accompanied with easily observed swelling or obscuration of anatomic structures. Twenty patients had lymphedema which interfered with their active daily life.

Brachial plexopathy {#sec2-10}
-------------------

Clinically symptomatic/significant brachial plexopathy was observed in 12.5% of the patients. Only six patients developed brachial plexopathy interfering with active daily life. There were none with disabling brachial plexopathy observed after a median follow-up of 42 months.

Discussion {#sec1-4}
==========

Hypofractionated RT was introduced to ease the burden of patients and hospitals alike. However, use of hypofractionation leads to unacceptably high percentage of severe complications.\[[@ref7][@ref8][@ref9]\] Fractional size of \>2 Gy produces unacceptable late adverse sequelae.\[[@ref10]\] Due to their close proximity to chest wall, certain organs/structures suffer radiation-induced toxicities. These late adverse effects can significantly impact the quality of life in long run. Opposed tangential portals with or without supraclavicular field expose structures such as heart, lungs, brachial plexus, and regional lymphatics to significant amounts of radiation doses. Moreover, all these structures are particularly sensitive to fractionation. As for this study, keeping in view the late reactions, the biologically effective doses delivered with two schedules came out to be 80.3 Gy for 40 Gy in 15 fractions and 75.3 Gy for 42.5 Gy in 16 fractions.

To add to this, there are certain patient-, disease-, and treatment-related factors which influence the risk of chest wall irradiation such as age, personal history of patient, extent of nodal dissection, number of nodes dissected, use of supraclavicular/axillary field, and so on. These factors have been shown by a number of studies to increase the incidence of normal tissue complications. However, the majorities were carried out in conjunction with conventional fractionation regimes. There is very scarce data on the relevance of these factors in the era of hypofractionated RT, especially in the postmastectomy settings, where the likelihood of normal tissue complications increases with time. Moreover, to collect data on how these factors influence the effects of hypofractionated RT on normal tissue functions was also one of the aims of this study.

First, for cardiac tissues \[[Table 3](#T3){ref-type="table"}\], we reported an incidence of 14.8% of ≥Gr2 late cardiac toxicity, with statistically significant difference when left-sided disease was compared with the right side (*P* \< 0.05). This is in agreement with Darby *et al*.\[[@ref11]\] study, who reported an increased risk of cardiac deaths after treatment for left-sided breast cancer. Age at irradiation has been demonstrated to increase the risk. Hooning *et al*.\[[@ref12]\] reported that younger age \<35 years have a relative risk of 6.5 as compared to the general population for radiation-induced heart disease. We, however, observed no statistically significant difference for cardiac toxicity for patients \<45 years versus \>45 years. King *et al*.\[[@ref13]\] showed that factors such as hypertension, being overweight, and diabetes influence the overall risk of radiation-induced heart injury. We too observed that 21 out of 47 patients with diabetes and 25 out of 53 hypertensives suffered ≥Gr2 cardiac toxicity with results being statistically significant. Furthermore, patients with body mass index (BMI) ≥25 had statistically significant late adverse effects. Smoking also increases the risk, with 60% of active/ex-smokers developing ≥Gr2 cardiac toxicity. Radiation potentiates the cardiotoxic effects of some chemotherapeutic agents such as anthracyclines, and this interaction is dose dependent.\[[@ref14]\] The total cumulative dose of anthracycline in our study was well below 360 mg/m^2^. Our trial found no statistically significant late adverse effect in patients receiving chemotherapy, with no influence of the type of regime utilized. Concerning hormonal therapy, no statistically significant difference was found.

###### 

Cardiac toxicity in association with demographic variables
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Second, for lung tissues \[[Table 4](#T4){ref-type="table"}\], we observed 10.2% of late ≥Gr2 adverse events at 42 months of median follow-up. Lind *et al*.\[[@ref15]\] reported that use of axillary/supraclavicular portals in addition to tangential portals increased the incidence of pulmonary complications. We reported statistically significant incidence of late pulmonary toxicity in those who received supraclavicular RT (*P* = 0.03) as compared to those who did not. Age and smoking have also been considered as risk factors contributing to radiation-induced lung injury.\[[@ref16][@ref17][@ref18][@ref19][@ref20][@ref21]\] In our series, although we observed no statistically significant effect of age on pulmonary adverse effects, smoking definitely potentiates the side effect of hypofractionation on pulmonary functions with 17 out of 35 smokers/ex-smokers suffering ≥Gr2 toxicity, the results being statistically significant (*P* \< 0.005). Lingos *et al*.\[[@ref22]\] found increased incidence of radiation-induced lung injury in patients receiving chemotherapy. The impact of hormonal therapy on radiation pneumonitis has also been demonstrated in a number of trials.\[[@ref23][@ref24]\] In our study, we found that both chemotherapy and hormonal therapy do increase the risk of lung injury when combined with hypofractionated RT. Being diabetic or hypertensive also increased the risk of pulmonary toxicity with statistically significant results for ≥Gr2 late lung toxicity.

###### 

Pulmonary toxicity in association with demographic variables
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Concerning lymphedema, various studies quote 5%--42% rate of lymphedema following breast cancer treatment.\[[@ref25]\] Risk increases when axillary dissection is combined with axillary RT. In our study, we reported the risk of clinically significant ≥Gr2 lymphedema at 28.7% \[[Table 5](#T5){ref-type="table"}\], and this risk was more in patients who underwent axillary dissection (57 out of 175), and especially increased in those who had ≥10 lymph nodes dissected (*P* = 0.0005). Other risk factors associated with increased incidence of lymphedema included smoking (*P* \< 0.05), BMI ≥25 (*P* \< 0.05), and hypertension (*P* \< 0.05). Segerström *et al*.\[[@ref26]\] found that being obese increased the risk of arm edema in patients. Böhler *et al*.\[[@ref27]\] in another series described hypertension as the risk factor for lymphedema after axillary surgery and RT. Adjuvant chemotherapy and hormonal therapy were not found to influence the risk of lymphedema in our study.

###### 

Association of lymphedema with different demographic variables
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Finally, regarding brachial plexopathy, there is a concern that hypofractionated schedules may be associated with the higher risk of late complications to the brachial plexus. The risk of developing brachial plexopathy after conventionally fractionated megavoltage RT is estimated to be below 1%.\[[@ref28][@ref29]\] Galecki *et al*.\[[@ref30]\] in a review article estimated that the risk of brachial plexopathy ranged from 1.7% up to 73% with the use of doses per fraction in the range from 2.2 to 4.58 Gy with the total doses between 43.5 and 60 Gy. They also concluded that surgical manipulations in the axilla and chemotherapy have to be taken into account as additional factors which may increase the risk of brachial plexopathy. In our present study, we observed an overall incidence of 30.6% \[[Table 6](#T6){ref-type="table"}\] for any Gr of brachial plexopathy at a maximum follow-up of 5 years, with 12.5% incidence of ≥Gr2 brachial plexopathy. The extent of axillary dissection in conjunction with use of supraclavicular field significantly influenced the appearance of clinically symptomatic brachial plexopathy with *P* \< 0.05. Other factors which increased the risk of brachial plexopathy included smoking (*P* = 0.00002), diabetes mellitus (*P* \< 0.05), and use of hormonal therapy (*P* = 0.007).

###### 

Association of brachial plexopathy with different variables
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Hypofractionated schedules have gained a great impetus in present times following the publications of Standardisation of Breast Radiotherapy A and B trials. These studies have equated hypofractionation with conventional regime following breast conservation therapy with limited data in postmastectomy settings. Although the normal tissues studied in this trial are sensitive to fractionation with α/β values of ≤3 Gy, we observed clinically few to none disabling adverse events even at a maximum follow-up period of 5 years. However, there are certain risk factors pertaining to patient, disease, and treatment such as smoking, hypertension, diabetes mellitus, BMI, extent of axillary dissection, and use of supraclavicular/axillary field and hormonal therapy, which significantly influence the development of cardiac, pulmonary, lymphedema, and brachial plexopathy and late adverse effects. Moreover, although these adverse events were symptomatic and interfered with active daily life of patient, they are manageable.

Conclusion {#sec1-5}
==========

Results from this study clearly support the use of hypofractionated RT regimes for chest wall irradiation in postmastectomy settings with no fear of disabling/nonmanageable long-term normal tissue complications although more longer follow-up data are still warranted.

Financial support and sponsorship {#sec2-11}
---------------------------------

Nil.

Conflicts of interest {#sec2-12}
---------------------

There are no conflicts of interest.
